It's not atypical for smaller biotechs to be acqui

It's not atypical for smaller biotechs to be acquired, if you are in the industry long enough, you are bound to be involved in a handful of companies that go the M&A route. I don't purport to know what the intentions are here, but suffice to say, none of us do. Will just need to see how it all plays out re: BLA, Amarex, partnerships for focused indications, M&A, etc.

What I do know is that Simes addition is a net positive imo. Continued positive moves by Cytodyn. Would be really difficult to see this any other way.